Yondelis is the brand name for an injection called Trabectedin, which has been used for antitumor chemotherapy medication to treat soft tissue sarcoma and ovarian cancer. Nato Pharma received provisional approval from US Food and Drug Administration (USFDA) for injection generic for Yondelis for the composition of 1mg/vial presentation. As per sales data, annual sales of $49.7 million of Yondelis in the US market year ended in June 2022. The consolidated net profit of Nato Pharma went up by 327.20 per cent to Rs 320.40 crore in the Apr-Jun quarter of FY22 and an increase in net sales by 115.60 per cent to Rs 884.60 crore in Apr-Jun FY21. On 17 August, the pharma company Natco’s shares fell by 0.57 per cent to Rs 651.30.

• LNG Imports in India Surged 10.5% During October 
• US Climate Financing Reaches $11 Billion in 2024
• Govt Likely to Surpass FY25 Direct Tax Target: CBDT Chief
• RVNL Receives Rs 295 Crore Contract from South Central Railway, Shares Trading Flat
• ACME Solar Shares Hit 10% Upper Circuit as Subsidiary Secures Rs 3,953 Crore Loan  

This pharma company is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing and marketing finished formulation of dose and active pharmaceutical ingredients (API). In 40 countries, the products are distributed in the market.